<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267942</url>
  </required_header>
  <id_info>
    <org_study_id>P75/4/2008</org_study_id>
    <nct_id>NCT01267942</nct_id>
  </id_info>
  <brief_title>Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Enhancin in Prevention of Postadenotonsillectomy Morbidity.</brief_title>
  <official_title>Single Intraoperative Intravenous Enhancin[Co-amoxiclav] Versus Postoperative Full Oral Course in Prevention of Post Adenotonsillectomy Morbidity:A Randomised Clinical Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Nairobi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Nairobi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Null hypothesis; The efficacy of Enhancin]Co-Amoxiclav given as a single intravenous dose at
      induction is not better than a five days oral course of the same given postoperatively in
      reducing postoperative morbidity after adenotonsillectomy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adenotonsillectomy results in morbidity that is reduced by the use of antibiotics.This study
      had the sole objective of comparing two route of administration to see which has superior
      results.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>POSTOPERATIVE FEVER</measure>
    <time_frame>OPERATION DAY TO 7 DAYS POSTOPERATIVELY</time_frame>
    <description>Temperature monitored at 1st ,4th and 7th postoperative days.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">126</enrollment>
  <condition>Adenotonsillar Hypertrophy,Under 12 Years.</condition>
  <arm_group>
    <arm_group_label>Intravenous intraoperative Enhancin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received a dose of intravenous Enhancin at induction and only oral Paracetamol in the postoperative period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Postoperative oral Enhancin.</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients received postoperative oral Enhancin for five days in addition to oral Paracetamol for the same duration. They did not receive an antibiotic during the operation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enhancin</intervention_name>
    <description>Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.
Oral dose of the same at the same dosage for the active comparator arm.</description>
    <arm_group_label>Intravenous intraoperative Enhancin</arm_group_label>
    <arm_group_label>Postoperative oral Enhancin.</arm_group_label>
    <other_name>Augmentin.</other_name>
    <other_name>Clavulin.</other_name>
    <other_name>Myoclav.</other_name>
    <other_name>Co- amoxiclav</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients below 12year scheduled to undergo adenotonsillectomy whose parents or
             guardians give consent for recruitment into the study.

        Exclusion Criteria:

          -  Non consenting parents or guardians. Antibiotic use in the week preceding surgery.
             Patients with co mordities. Known allergies to Co-amoxiclav. Patients who develop
             complication that warrant change of antibiotic.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Musyoka D Mutiso, mmed ent</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health, Kenya</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kenyatta National Hospital.</name>
      <address>
        <city>Nairobi.</city>
        <zip>P.O.BOX 20723</zip>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
  </location_countries>
  <reference>
    <citation>Colreavy MP, Nanan D, Benamer M, Donnelly M, Blaney AW, O'Dwyer TP, Cafferkey M. Antibiotic prophylaxis post-tonsillectomy: is it of benefit? Int J Pediatr Otorhinolaryngol. 1999 Oct 15;50(1):15-22.</citation>
    <PMID>10596882</PMID>
  </reference>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2010</study_first_submitted>
  <study_first_submitted_qc>December 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2010</study_first_posted>
  <last_update_submitted>December 28, 2010</last_update_submitted>
  <last_update_submitted_qc>December 28, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>ISSAC MUTHURE MACHARIA/PROFESSOR.</name_title>
    <organization>University of Nairobi.</organization>
  </responsible_party>
  <keyword>Adenotonsillectomy.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin-Potassium Clavulanate Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

